Arvind Kush - 14 Sep 2023 Form 3 Insider Report for RayzeBio, Inc. (RYZB)

Role
Chief Financial Officer
Signature
/s/ Jeff Woodley, Attorney-in-fact
Issuer symbol
RYZB
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
3
Filing time
14 Sep 2023, 20:39:08 UTC
Next filing
17 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RYZB Common Stock 77,557 14 Sep 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RYZB Employee Stock Option (Right to Buy) 14 Sep 2023 CommonStock 301,745 $3.24 Direct F1
holding RYZB Employee Stock Option (Right to Buy) 14 Sep 2023 Common Stock 149,777 $3.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is subject to an early exercise provision and is immediately exercisable. 25% of the shares vested on December 22, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2 The option is subject to an early exercise provision and is immediately exercisable. Vesting is monthly over a 48-month period starting January 1, 2023 in equal monthly amounts.

Remarks:

Exhibit 24 - Power of Attorney